Infección pulmonar por Mycobacterium abscessus complex

Eliana Maldonado Lara

Resumen


Las micobacterias no tuberculosas (MNT) son ubicuas. Factores del huésped, defectos del sistema inmunitario, alteraciones estructurales del parénquima pulmonar y factores medioambientales influyen en el desarrollo de la enfermedad. Se presenta el caso de un paciente que cumple con los criterios diagnósticos propuestos para infección pulmonar secundaria a una MNT de crecimiento rápido tipo Mycobacterium abscessus complex, que muestra una amplia resistencia intrínseca y requiere terapia antimicrobiana combinada basada en macrólidos y de la larga duración, con unas bajas tasas de negativización de los cultivos de esputo.

Palabras clave


micobacterias no tuberculosas; Mycobacterium abscessus complex; macrólidos

Texto completo:

PDF

Referencias


Koh WJ, Stout JE, Yew WW. Advances in the management of pulmonary disease due to Mycobacterium abscessus complex. Int J Tuberc Lung Dis [Internet]. 2014;18(10):1141-8. Disponible en: http://dx.doi.org/10.5588/ijtld.14.0134.

Johnson MM, Odell JA. Nontuberculous mycobacterial pulmonary infections. J Thorac Dis. 2014;6(3):210-20.

Kwon YS. Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease. Korean J Med. 2012;82(3):274.

Medjahed H, Gaillard JL, Reyrat JM. Mycobacterium abscessus: a new player in the mycobacterial field. Trends Microbiol [Internet]. 2010;18(3):117-23. Disponible en: http://dx.doi.org/10.1016/j.tim.2009.12.007.

Aksamit TR, Philley JV, Griffith DE. Nontuberculous mycobacterial (NTM) lung disease: The top ten essentials. Respir Med [Internet]. 2014;108(3):417-25. Disponible en: http://dx.doi.org/10.1016/j.rmed.2013.09.014.

Lee MR, Sheng WH, Hung CC, Yu CJ, Lee LN, Hsueh PR. Mycobacterium abscessus Complex Infections in Humans. Emerg Infect Dis [Internet]. 2015;21(9)1638-46. Disponible en: http://wwwnc.cdc.gov/eid/article/21/9/14-1634_article.htm.

Koh WJ, Yu CM, Suh GY, Chung MP, Kim H, Kwon OJ, et al. Pulmonary TB and NTM lung disease: comparison of characteristics in patients with AFB smear-positive sputum. Int J Tuberc Lung Dis. 2006;10(9):1001-7.

Obregón-Henao A, Arnett KA, Henao-Tamayo M, Massoudi L, Creissen E, Andries K, et al. Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models. Antimicrob Agents Chemother. 2015;59(11):6904-12.

Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B. Mycobacterium abscessus: A new antibiotic nightmare. J Antimicrob Chemother. 2012;67(4):810-8.

Koh WJ, Jeong BH, Kim SY, Jeon K, Park KU, Jhun BW, et al. Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease. Clin Infect Dis [Internet]. 2017;64(3):309-16. Disponible en: http://cid.oxfordjournals.org/lookup/doi/10.1093/cid/ciw724.

Aziz DB, Low JL, Wu ML, Gengenbacher M, Teo JWP, Dartois V, et al. Rifabutin Is active against Mycobacterium abscessus Complex. Antimicrob Agents Chemother. 2017;61(6).

Mukherjee D, Wu ML, Teo JWP, Dick T. Vancomycin and Clarithromycin Show Synergy against Mycobacterium abscessus In Vitro. Antimicrob Agents Chemother. 2017;61(12).

Park J, Cho J, Lee CH, Han SK, Yim JJ. Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense. Clin Infect Dis [Internet]. 2017;64(3):301-8. Disponible en: http://cid.oxfordjournals.org/lookup/doi/10.1093/cid/ciw723

Pasipanodya JG, Ogbonna D, Ferro BE, Magombedze G, Srivastava S, Deshpande D, et al. Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence. Antimicrob Agents Chemother [Internet]. 2017;61(11):AAC.01206-17. Disponible en: http://aac.asm.org/lookup/doi/10.1128/AAC.01206-17

Alvarez-Uria G. Lung disease caused by nontuberculous mycobacteria. Curr Opin Pulm Med. 2010;16(3):251-6.

McShane PJ, Glassroth J. Pulmonary disease due to nontuberculous mycobacteria current state and new insights. Chest. 2015;148(6):1517-27.

Benwill JL, Wallace RJ Jr. Mycobacterium abscessus: challenges in diagnosis and treatment. Curr Opin Infect Dis [Internet]. 2014;27(6):506-10. Disponible en: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00001432-201412000-00007.

Brown-Elliott BA, Vasireddy S, Vasireddy R, Iakhiaeva E, Howard ST, Nash K, et al. Utility of sequencing the erm(41) gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate clarithromycin MICs. J Clin Microbiol. 2015;53(4):1211-5.

Rubio M, March F, Garrigó M, Moreno C, Español M, Coll P. Inducible and acquired clarithromycin resistance in the mycobacterium abscessus complex. PLoS One. 2015;10(10):e0140166.

Kehrmann J, Kurt N, Rueger K, Bange FC, Buer J. GenoType NTM-DR for Identifyng Mycobacterium abscessus Subspecies and Determining Molecular Resistance. J Clin Microbiol. 2016;54(6):1653-5.

Harada T, Akiyama Y, Kurashima A, Nagai H, Tsuyuguchi K, Fujii T, et al. Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases. J Clin Microbiol. 2012;50(11):3556-61.




DOI: http://dx.doi.org/10.30789/rcneumologia.v30.n1.2018.301

Métricas de artículo

Vistas de resumen
0




Cargando métricas ...

Enlaces refback

  • No hay ningún enlace refback.


Asociación Colombiana de Neumología y Cirugía de Tórax.
Dirección: Carrera 7 Bis # 123-52 Of. 202, Teléfono: 57(1)3222335 - Bogotá - Colombia.
Sistema OJS - Metabiblioteca |